EVOMELA Drug Patent Profile

When do Evomela patents expire, and what generic alternatives are available?

Evomela is a drug marketed by Acrotech Biopharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and five patent family members in twenty-two countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evomela

A generic version of EVOMELA was approved as melphalan hydrochloride by MYLAN INSTITUTIONAL on June 9^th, 2009.

Summary for EVOMELA

International Patents:	105
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EVOMELA

Paragraph IV (Patent) Challenges for EVOMELA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EVOMELA	Powder for Injection	melphalan hydrochloride	50 mg/vial	207155	1	2017-09-08

US Patents and Regulatory Information for EVOMELA

EVOMELA is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes			Y

International Patents for EVOMELA

See the table below for patents covering EVOMELA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013334921
Brazil	112015008954
Canada	2888822
Chile	2015001016

Supplementary Protection Certificates for EVOMELA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	3/2023	Austria		PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720	202240050	Slovenia		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1669/001; DATE OF NATIONAL AUTHORISATION: 20220817; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2701720	23C1000	France		PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720	SPC/GB23/004	United Kingdom		PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818

Investment Scenario, Market Dynamics, and Financial Trajectory for EVOMELA (melphalan)

Last updated: February 3, 2026

Executive Summary

EVOMELA (melphalan for injection, encapsulated in a novel lipid-based formulation) is an FDA-approved chemotherapeutic agent primarily indicated for high-dose chemotherapy in multiple myeloma and lymphoma prior to stem cell transplant. This comprehensive analysis evaluates investment prospects, considering market positioning, competitive landscape, regulatory trajectory, and financial forecasts. EVOMELA's unique delivery platform, market dynamics driven by hematologic cancers, and evolving treatment paradigms inform its growth trajectory. Current valuation estimates, potential market expansion, and risks are also examined.

---

What is EVOMELA and its Therapeutic Indications?

EVOMELA is a proprietary lipid encapsulation form of melphalan, designed for intravenous administration. It enhances drug stability and offers specific pharmacokinetic advantages over traditional formulations.

Approved Indication	Line of Therapy	Key Patient Population
High-dose chemotherapy prior to autologous stem cell transplantation in multiple myeloma	First-line in eligible patients	Adults with multiple myeloma or non-Hodgkin lymphoma

Manufactured by Secura Bio Inc.* (by agreement), EVOMELA aims to improve safety and efficacy profiles relative to conventional melphalan.

---

Market Landscape & Dynamics

Global Hematologic Malignancy Market Overview

Segment	Projected CAGR (2021-2028)	Market Size (2021)	Key Drivers
Multiple Myeloma	7.1%	USD 19.5B	Increasing prevalence, expanding treatment options
Non-Hodgkin Lymphoma	4.8%	USD 16.2B	Improved diagnostics, targeted therapies
Autologous Stem Cell Transplant	N/A (procedure-driven)	USD 3.5B	Rising transplantation procedures

Sources: Fortune Business Insights, 2022[1]; GlobalData, 2022[2]

Current Market Position of EVOMELA

• Competitive Therapeutics: Traditional melphalan (Alkermes' Evomela, marketed as JEMPERLI in some regions), modified high-dose chemotherapies, targeted agents.
• Advantages of EVOMELA: Enhanced pharmacokinetics, reduced toxicity, ease of administration.
• Market Penetration: Limited but growing within transplant centers; adoption driven by clinical trial data and physician preference.

Key Market Drivers and Barriers

Drivers	Barriers
Efficacy in high-dose therapy	Competition from generic formulations
Improved safety profile	Cost considerations
Rising number of transplant procedures	Patent constraints and intellectual property issues
Expanding indications	Physician familiarity with traditional melphalan

Note: Cost-effectiveness and reimbursement policies significantly influence adoption.

---

Investment Opportunities and Risks

Potential Market Expansion

• New Indications: Potential label expansion into multiple myeloma maintenance, relapsed/refractory settings.
• Geographic Expansion: Growing markets in Asia-Pacific and Europe, subject to regulatory approval and market access strategies.
• Combination Therapies: Opportunities to combine EVOMELA with novel agents for synergistic effects.

Regulatory and Patent Landscape

Current Status	Implications for Investors
FDA-approved; orphan drug designation	Provides market exclusivity until 2030; reduces competitive risk
Patent coverage until 2028 (pending extensions)	Potential for patent extension filings
Similar formulations in early development	Future biosimilars or generics may erode market share

Regulatory pathways for additional indications under pursuit could boost market size.

Market Risks

• Competitive Market Entrants: Development of biosimilar or alternative chemotherapeutics.
• Pricing & Reimbursement: Payer push for cost containment.
• Clinical Efficacy: Dependence on clinical trial outcomes for broader adoption.
• Regulatory Barriers: Delays or denials for new indications.

---

Financial Trajectory and Forecasts

Revenue Projections (2023–2028)

Year	Estimated Global Sales (USD Million)	Growth Rate	Assumptions
2023	150	15%	Initial market expansion post-initial adoption
2024	173	15.3%	Growing transplant utilization; new country approvals
2025	200	15.6%	Additional indications and cost negotiations
2026	230	15%	Market maturity; potential for further indication expansion
2027	265	15.2%	Competitive landscape stabilizes
2028	305	15.1%	Potential market saturation; patent considerations

Note: These estimates assume a modest but steady increase driven by market adoption and indications.

Cost Structure and Profitability

Cost Components	Approximate % of Revenue	Key Factors
Manufacturing & Supply	25%	Scale-driven efficiencies; raw material costs
R&D & Regulatory Filings	10%	For indication expansion, lifecycle management
Marketing & Distribution	20%	Market penetration efforts
General & Administrative	15%	Corporate overhead

Projected gross margins are estimated at 60–65%, with net margins improving as scale increases.

---

Comparative Analysis: EVOMELA versus Competitors

Attribute	EVOMELA (Melphalan Liposomal)	Conventional Melphalan	Other High-Dose Chemotherapies
Delivery Platform	Liposomal encapsulation	Free acid form	Varies
Pharmacokinetics	Longer half-life, targeted	Standard biotransformation	Varies
Safety Profile	Improved, reduced GI toxicity	Standard toxicity profiles	Varies
Regulatory Status	FDA approved	Off-patent or generic	Varies
Market Penetration	Niche, emerging	Widely used, generic	Established, with new entrants

---

Comparison of Investment Drives and Barriers

Drivers	Barriers
Efficacy and safety advantages	Price sensitivity
Growing transplant and myeloma markets	Competition from generics
Potential for label expansions	Patent expiry risks
Favorable reimbursement policies	Clinical trial delays

---

FAQs

Q1: What are the main factors influencing EVOMELA's market future?
A1: Adoption rate in transplant centers, regulatory approvals for new indications, competition from generics, pricing strategies, and expanding indications.

Q2: How does EVOMELA's pharmacokinetics compare to traditional melphalan?
A2: Liposomal encapsulation prolongs half-life, enhances targeted delivery, potentially reduces toxicity, and improves efficacy over traditional formulations.

Q3: What is the patent landscape and its impact on EVOMELA?
A3: Protected until approximately 2028 with potential extensions; patent expiry could lead to generic competition, impacting revenue.

Q4: Could EVOMELA benefit from combination therapy approvals?
A4: Yes. Combining EVOMELA with newer agents like immunomodulators or monoclonal antibodies could expand its use cases, provided clinical trials demonstrate benefit.

Q5: What are the main risks in investing in EVOMELA?
A5: Competitive pressures, pricing and reimbursement challenges, regulatory delays, patent expiration, and slow adoption.

---

Key Takeaways

• Market Position: EVOMELA holds a niche but growing position in high-dose chemotherapy for hematologic malignancies.
• Growth Opportunities: Label expansions, geographic growth, and combination therapies present substantial upside.
• Competitive Risks: The upcoming patent expiration and potential biosimilar entrants pose long-term threats.
• Financial Outlook: Moderate but steady revenue growth projected at approximately 15% annually over the next five years, contingent upon market uptake and regulatory success.
• Strategic Considerations: Investors should monitor regulatory developments, reimbursement policies, and competitors’ pipeline movements.

---

References

1. Fortune Business Insights. Global Hematologic Malignancies Market Size, Share & Industry Analysis. 2022.
2. GlobalData. Hematalogic Oncology Pipeline Analysis. 2022.